Livagen

Mechanism of Action

Livagen's proposed mechanism is the standard Khavinson short-peptide bioregulator model applied to hepatic tissue. The framework, developed at the St. Petersburg Institute of Bioregulation and Gerontology across roughly 35 years, proposes three nested levels of action: (1) membrane permeation, (2) nuclear localisation, and (3) sequence-selective chromatin modulation.

Level 1 — Passive membrane permeation. At 447 daltons (H-Lys-Glu-Asp-Ala-OH), Livagen is small enough and sufficiently polar to cross phospholipid bilayers without active transport. Khavinson's tritiated-peptide distribution studies — conducted in rodents across multiple bioregulator tetrapeptides — reported rapid tissue uptake following intraperitoneal or oral administration, with measurable radioactivity recovered from liver, thymus, brain, and testis within minutes (Khavinson et al., 2014). Those experiments did not distinguish intact peptide from amino-acid catabolites, so the claim that Livagen reaches the hepatocyte nucleus intact rests on inference rather than direct structural confirmation in target tissue.

Level 2 — Nuclear import. Khavinson's model argues that once inside the hepatocyte, the tetrapeptide diffuses through nuclear pores and accumulates in the nucleoplasm. Fluorescently labelled bioregulator peptides co-localise with chromatin in cultured cells in some Russian publications, though the fluorescence work is difficult to reconcile with standard endosomal-trafficking data in Western cell biology. There is no karyopherin-based active nuclear import pathway for Livagen — the claim is that passive diffusion is sufficient for a peptide this small.

Level 3 — Chromatin modulation. This is the most distinctive and controversial part of the Khavinson framework. The group reports that specific tetrapeptide sequences bind specific chromatin regions via base-pair-level contacts with exposed histone tails and/or B-form DNA, producing sequence-selective chromatin decondensation and preferential up-regulation of silenced age-associated genes (Khavinson et al., 2011; Solovyev et al., 2013). In the case of Livagen specifically, Russian publications describe modulation of rDNA expression in liver cells and changes in heterochromatin organisation in hepatocytes from aged rats after KEDA treatment (Khavinson and Malinin, 2005). These claims require contemporary molecular-biology validation — co-crystal structures, genome-wide ChIP-seq on tagged peptide, and chemically defined rescue experiments — that has not been published.

Alternative framing. A more conservative interpretation treats Livagen as a source of constituent amino acids (lysine, glutamate, aspartate, alanine) delivered in a rapidly absorbed short-peptide form. In that framing, the biological effects described in Russian papers could reflect (a) acute substrate delivery for hepatic protein synthesis after peptide hydrolysis, (b) non-specific signalling effects of the individual amino acids (glutamate as an excitatory neurotransmitter, aspartate as a gluconeogenic substrate, lysine for collagen synthesis), or (c) preparation-specific contaminants from the manufacturing route. None of these mechanisms would make Livagen unique — any dipeptide or tetrapeptide source would be equivalent.

Receptor pharmacology. No G-protein-coupled receptor, nuclear receptor, or defined enzyme target has been identified for Livagen. It does not bind known growth-factor receptors. It is not a substrate or inhibitor of any mapped cytochrome P450. It does not interact with FXR, PPARα, or the other nuclear receptors that dominate modern hepatic pharmacology. The absence of a defined target is a feature, not a bug, within the Khavinson framework — bioregulators are proposed to act through chromatin rather than through classical receptor pharmacology — but it is also why Western pharmaceutical companies have not picked up the molecule for development.

Relation to longer hepatoprotective peptides. Livagen occupies a specific niche within the Khavinson programme. Stamakort and similar "liver peptide" products are polypeptide extracts prepared from calf or porcine liver — undefined mixtures by modern standards, positioned as organ-specific bioregulators. Livagen was synthesised as a defined short sequence intended to reproduce the core bioregulator activity of these extracts in a pure, chemically characterised form. Whether it succeeds is the open question. It is mechanistically distinct from TUDCA, from SAMe, and from silymarin — none of those compounds pretend to enter the nucleus and modulate chromatin.

Livagen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "liver bioregulator" intended to normalise age-related and stress-related changes in hepatic tissue. It is usually described in Khavinson-family publications as the tetrapeptide Lys-Glu-Asp-Ala (KEDA), sometimes written as H-Lys-Glu-Asp-Ala-OH or K-E-D-A, and is one of the shortest members of the large peptide-bioregulator family that also includes Epitalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg), Vilon (Lys-Glu), and Thymogen (Glu-Trp). Within that framework, Livagen is the "sibling" peptide to a longer polypeptide preparation called Stamakort/Cortex peptide — which is a porcine liver extract — and is sold in the post-Soviet supplement channel as a dietary capsule alongside the other Khavinson tetrapeptides.

Outside Russia and a small number of former-Soviet-state pharmacology journals, Livagen is not a registered drug, not a dietary ingredient reviewed by FDA, EMA or any major English-language regulator, and not a member of the WADA Prohibited List. There are no phase II or phase III randomised trials for Livagen indexed in PubMed or on ClinicalTrials.gov. The published Russian work — most of it co-authored by Khavinson and published in Bulletin of Experimental Biology and Medicine between 2002 and 2015 — describes in vitro chromatin effects and small rodent studies showing modulation of hepatic gene expression, hepatocyte proliferation markers, and restoration of age-related changes in liver morphology (Khavinson et al., 2003; Khavinson and Malinin, 2005; Anisimov et al., 2010).

The central therapeutic claim Khavinson's group makes for Livagen is that the Lys-Glu-Asp-Ala tetrapeptide — small enough to cross plasma and nuclear membranes passively — can enter hepatocyte nuclei, interact with chromatin via sequence-selective contacts with histones and DNA, and preferentially activate transcription programmes that are normally suppressed by age and chronic stress. That model predicts selective reversal of age-related hepatic dysfunction without mitogenic or pro-inflammatory effects. The hypothesis is interesting and internally consistent within the Khavinson programme, but the molecular validation required by contemporary structural biology — co-crystal structures, ChIP-seq in hepatocyte models, chemically defined knock-out rescue — has not been published in Western-indexed literature. Readers should understand Livagen as an investigational Russian bioregulator with a sustained 25-year research programme inside one institute and minimal replication outside it.

BodyHackGuide covers Livagen because it is frequently sold online — usually as 20 mg capsules containing roughly 2–4 mg of actual peptide per capsule — and because it appears in longevity-stack discussions alongside better-validated compounds. We describe what is known, what is claimed, and what is missing, and we steer readers who want evidence-graded hepatic support toward interventions with stronger replication: weight management, alcohol reduction, NAD+ precursors for mitochondrial support, Berberine and metformin for insulin-sensitising metabolic benefit in non-alcoholic fatty liver disease, and TUDCA (Tauroursodeoxycholic acid) for cholestatic biochemistry. Livagen is a plausible hypothesis. It is not, at this writing, an evidence-graded hepatic therapy.

IUPAC Name

L-Lysyl-L-glutamyl-L-aspartyl-L-alanine

CAS Number

109028-17-7

Molecular Formula

Lys-Glu-Asp-Ala

Molecular Mass

460.45 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Livagen Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility